Folic Acid-Conjugated Europium Complexes as Luminescent Probes for Selective Targeting of Cancer Cells

2015 ◽  
Vol 58 (4) ◽  
pp. 2003-2014 ◽  
Author(s):  
Silvio Quici ◽  
Alessandro Casoni ◽  
Francesca Foschi ◽  
Lidia Armelao ◽  
Gregorio Bottaro ◽  
...  
Keyword(s):  
Folic Acid ◽  
Cancer Cells ◽  
Europium Complexes ◽  
Luminescent Probes ◽  
Selective Targeting

scholarly journals Folic acid conjugates of a bleomycin mimic for selective targeting of folate receptor positive cancer cells

2019 ◽  
Vol 29 (15) ◽  
pp. 1922-1927 ◽  
Author(s):  
Arjan Geersing ◽  
Reinder H. de Vries ◽  
Gerrit Jansen ◽  
Marianne G. Rots ◽  
Gerard Roelfes
Keyword(s):  
Folic Acid ◽  
Cancer Cells ◽  
Folate Receptor ◽  
Selective Targeting

scholarly journals Highly stable folic acid functionalized copper-nanocluster/silica nanoparticles for selective targeting of cancer cells

RSC Advances ◽  
2020 ◽  
Vol 10 (52) ◽  
pp. 31463-31469
Author(s):  
Xiaoming Fang ◽  
Yanhua Huang ◽  
Dan Yu ◽  
Caiwen Shi ◽  
Ming Liu
Keyword(s):  
Folic Acid ◽  
Silica Nanoparticles ◽  
Cancer Cells ◽  
High Stability ◽  
Cell Imaging ◽  
Fluorescence Properties ◽  
Selective Targeting ◽  
Good Biocompatibility

Folic acid functionalized CuNCs@SiO2 nanocomposites with superior fluorescence properties, high stability and good biocompatibility for targeted cell imaging.

scholarly journals Folic Acid-Targeted Paclitaxel-Polymer Conjugates Exert Selective Cytotoxicity and Modulate Invasiveness of Colon Cancer Cells

Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 929
Author(s):  
Antonella Grigoletto ◽  
Gabriele Martinez ◽  
Daniela Gabbia ◽  
Tommaso Tedeschini ◽  
Michela Scaffidi ◽  
...  
Keyword(s):  
Folic Acid ◽  
Cancer Cells ◽  
Pharmacokinetic Profile ◽  
Strong Impact ◽  
Passive Targeting ◽  
Drug Conjugates ◽  
Tumor Delivery ◽  
The Right ◽  
Polymer Drug Conjugates ◽  
Ht 29

Although selective tumor delivery of anticancer drugs has been sought by exploiting either passive targeting or by ligand-mediated targeting, a selective anticancer therapy remains an unmet medical need. Despite the advances which have been achieved by nanomedicines, nanosystems such as polymer-drug conjugates still miss the goal of clinical efficacy. In this study, we demonstrated that polymer-drug conjugates require a thoroughly chemical design and the right targeting agent/polymer ratio to be selective and effective towards cancer cells. In particular, two PEG conjugates carrying paclitaxel and targeted with different folic acid (FA)/PEG ratios (one or three) were investigated. The cytotoxicity study in positive (HT-29) and negative (HCT-15) FA receptor (FR)-cell lines demonstrated that the conjugates with one or three FAs were 4- or 28-fold more active in HT-29 cells, respectively. The higher activity of the 3-FA conjugate was confirmed by its strong impact on cell cycle arrest. Furthermore, FA targeting had a clear effect on migration and invasiveness of HT-29 cells, which were significantly reduced by both conjugates. Interestingly, the 3-FA conjugate showed also an improved pharmacokinetic profile in mice. The results of this study indicate that thorough investigations are needed to optimize and tune drug delivery and achieve the desired selectivity and activity towards cancer cells.

scholarly journals Novel TNBC-Targeted DOX-Arsonoliposomes

Proceedings ◽  
2020 ◽  
Vol 78 (1) ◽  
pp. 17
Author(s):  
Maria Mantzari ◽  
Foteini Gartziou ◽  
Eleni Lambrou ◽  
Spyridon Mourtas ◽  
Paraskevi Zagana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Folic Acid ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Entrapment Efficiency ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Selective Toxicity ◽  
First Results

Arsonoliposomes (ARSL) constitute a particular class of liposomes that incorporate arsonolipids (ARS) into their membranes. ARSL realize selective toxicity to cancer cells; thus, they are an important tool in the treatment of cancer. Folic acid (FA) is widely used in targeted drug delivery due to its high affinity for the folate receptors that are overexpressed in cancer cell membranes. The aim of our studies was to develop novel triple-negative breast cancer (TNBC)-targeted ARSL by incorporating folic acid-conjugated polyethylene-glycol PEG-lipid (FA-PEG-lipid) into their membrane and loading them with anticancer drug doxorubicin (DOX). ARSL incorporating 0.1 mol% of FA-PEG-lipid were prepared and loaded with DOX, using the active loading protocol. They were characterized for their size distribution, zeta potential and drug entrapment efficiency (%). Their cytotoxic activity towards TNBC cell lines, particularly MDA-MB-231 (epithelial human breast cancer cells) and MCF7 (human breast cancer cells), was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide MTT-assay. The first results demonstrated enhanced toxicity of this novel type of ARSL towards cancer cells, which is particularly interesting and deserves further exploitation.

Gold nanoparticle-enhanced near infrared fluorescent nanocomposites for targeted bio-imaging

RSC Advances ◽  
2015 ◽  
Vol 5 (1) ◽  
pp. 20-26 ◽  
Author(s):  
Hao Cheng ◽  
Chuanxi Wang ◽  
Zhenzhu Xu ◽  
Huihui Lin ◽  
Chi Zhang
Keyword(s):  
Folic Acid ◽  
Cancer Cells ◽  
Gold Nanoparticle ◽  
Near Infrared ◽  
Water Solubility ◽  
Imaging Agents ◽  
Nir Fluorescence ◽  
Target Imaging ◽  
Bio Imaging ◽  
Low Toxicity

Folic acid-conjugated nanocomposites with NIR fluorescence, water-solubility, and low toxicity are prepared and used as target-imaging agents for cancer cells.

Folic acid-conjugated green luminescent carbon dots as a nanoprobe for identifying folate receptor-positive cancer cells

Talanta ◽  
2018 ◽  
Vol 183 ◽  
pp. 39-47 ◽  
Author(s):  
Junli Zhang ◽  
Xuewei Zhao ◽  
Ming Xian ◽  
Chuan Dong ◽  
Shaomin Shuang
Keyword(s):  
Folic Acid ◽  
Cancer Cells ◽  
Carbon Dots ◽  
Folate Receptor

scholarly journals TCR β chain–directed bispecific antibodies for the treatment of T cell cancers

2021 ◽  
Vol 13 (584) ◽  
pp. eabd3595 ◽  
Author(s):  
Suman Paul ◽  
Alexander H. Pearlman ◽  
Jacqueline Douglass ◽  
Brian J. Mog ◽  
Emily Han-Chung Hsiue ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
B Cell ◽  
Cancer Cells ◽  
Cell Cancer ◽  
Bispecific Antibodies ◽  
Target Antigen ◽  
Human T Cell ◽  
Selective Targeting ◽  
Β Chain

Immunotherapies such as chimeric antigen receptor (CAR) T cells and bispecific antibodies redirect healthy T cells to kill cancer cells expressing the target antigen. The pan-B cell antigen–targeting immunotherapies have been remarkably successful in treating B cell malignancies. Such therapies also result in the near-complete loss of healthy B cells, but this depletion is well tolerated by patients. Although analogous targeting of pan-T cell markers could, in theory, help control T cell cancers, the concomitant healthy T cell depletion would result in severe and unacceptable immunosuppression. Thus, therapies directed against T cell cancers require more selective targeting. Here, we describe an approach to target T cell cancers through T cell receptor (TCR) antigens. Each T cell, normal or malignant, expresses a unique TCR β chain generated from 1 of 30 TCR β chain variable gene families (TRBV1 to TRBV30). We hypothesized that bispecific antibodies targeting a single TRBV family member expressed in malignant T cells could promote killing of these cancer cells, while preserving healthy T cells that express any of the other 29 possible TRBV family members. We addressed this hypothesis by demonstrating that bispecific antibodies targeting TRBV5-5 (α-V5) or TRBV12 (α-V12) specifically lyse relevant malignant T cell lines and patient-derived T cell leukemias in vitro. Treatment with these antibodies also resulted in major tumor regressions in mouse models of human T cell cancers. This approach provides an off-the-shelf, T cell cancer selective targeting approach that preserves enough healthy T cells to maintain cellular immunity.

Sign in / Sign up

Export Citation Format

Share Document